Blood cancer patients on CAR-T therapy long-term study
Part of Blood & lymphatic, Cancer clinical trials.
This study is for people with blood cancers who are treated with CAR-T cell therapy. Researchers will follow participants over time to learn more about how this therapy works in the real world.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer, like leukemia, lymphoma, or multiple myeloma.
- You have received or will receive CAR-T cell therapy.
- You are willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests a type of immunotherapy called CAR-T cells, which are specially engineered white blood cells designed to find and destroy cancer cells. It is for people with blood cancers that have come back or not responded to other treatments and who have few remaining options.
This study looks at how patients with blood cancers are managed in real life when they receive CAR-T cell therapy. It helps doctors learn more about how well these treatments work outside of clinical trials.
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
This study looks at how your immune system responds to CAR-T cell therapy, a treatment that uses your own immune cells to fight certain cancers. By participating, you help researchers learn more about how this therapy affects the body, which could improve care for future patients.
This study follows people who have already received a CRISPR CAR T cell therapy to monitor their long-term health and any side effects. It helps doctors understand how these treatments work over time.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.